The cytosine base editor (CBE) has shown promise as a gene editing tool for gene therapy, as it can convert cytidine to thymidine. Adeno-associated virus (AAV) has been widely used for in vivo gene therapy, but its limited 4.7 kb packing capacity presents challenges in delivering CBE by a single AAV. To address this, one feasible solution is to split CBE into two sections for dual-AAV delivery. In this study, we utilized BE3 as an example and constructed 22 potential split-BE3 pairs with the combination of 11 splitting sites and two split-inteins (Npu and Rma). These split-BE3 pairs were initially screened in the green fluorescent protein (GFP) reporter system, with six split-BE3 pairs selected for further evaluation. The subsequent screening of split-BE3 pairs was performed at two endogenous sites in 293T and HeLa cells, revealing that the split-BE3-Rma674, split-BE3-Rma713, and split-BE3-Rma1005 displayed effective C-to-T conversion after transfection. The effectiveness of dual-AAV split-BE3 was further validated in culture cells and adult mouse eyes. Of note, the split-BE3-Rma674 demonstrated the most efficient C-to-T editing after AAV infection, with a maximal editing efficiency of 23.29% ± 10.98% in the mouse retinal pigment epithelium cells in vivo. Overall, our study presents a novel split-BE3 system with effective C-to-T conversion, which could be applied to CBE-based in vivo gene therapy.
Get full access to this article
View all access options for this article.
References
1.
JacksonM, MarksL, MayGHW, et al.The genetic basis of disease. Essays Biochem, 2018; 62(5):643–723; doi: 10.1042/EBC20170053
2.
MendellJR, Al-ZaidySA, Rodino-KlapacLR, et al.Current clinical applications of in vivo gene therapy with AAVs. Mol Ther, 2021; 29(2):464–488; doi: 10.1016/j.ymthe.2020.12.007
3.
TangR, XuZ. Gene therapy: A double-edged sword with great powers. Mol Cell Biochem, 2020; 474(1–2):73–81; doi: 10.1007/s11010-020-03834-3
4.
DunbarCE, HighKA, JoungJK, et al.Gene therapy comes of age. Science, 2018; 359(6372):eaan4672; doi: 10.1126/science.aan4672
5.
KomorAC, KimYB, PackerMS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016; 533(7603):420–424; doi: 10.1038/nature17946
6.
GaudelliNM, KomorAC, ReesHA, et al.Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature, 2017; 551(7681):464–471; doi: 10.1038/nature24644
7.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019; 576(7785):149–157; doi: 10.1038/s41586-019-1711-4
8.
YangB, YangL, ChenJ. Development and application of base editors. CRISPR J, 2019; 2(2):91–104; doi: 10.1089/crispr.2019.0001
9.
MollaKA, YangY. CRISPR/Cas-mediated base editing: Technical considerations and practical applications. Trends Biotechnol, 2019; 37(10):1121–1142; doi: 10.1016/j.tibtech.2019.03.008
10.
ReesHA, LiuDR. Base editing: Precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet, 2018; 19(12):770–788; doi: 10.1038/s41576-018-0059-1
11.
KuscuC, ParlakM, TufanT, et al.CRISPR-STOP: Gene silencing through base-editing-induced nonsense mutations. Nat Methods, 2017; 14(7):710–712; doi: 10.1038/nmeth.4327
12.
BillonP, BryantEE, JosephSA, et al.CRISPR-mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons. Mol Cell, 2017; 67(6):1068–1079 e4; doi: 10.1016/j.molcel.2017.08.008
13.
GapinskeM, LuuA, WinterJ, et al.CRISPR-SKIP: Programmable gene splicing with single base editors. Genome Biol, 2018; 19(1):107; doi: 10.1186/s13059-018-1482-5
14.
MaY, YuanJ, ChangX. Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. STAR Protoc, 2020; 1(1):100005; doi: 10.1016/j.xpro.2019.100005
15.
HustedtN, DurocherD. The control of DNA repair by the cell cycle. Nat Cell Biol, 2016; 19(1):1–9; doi: 10.1038/ncb3452
16.
HaapaniemiE, BotlaS, PerssonJ, et al.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med, 2018; 24(7):927–930; doi: 10.1038/s41591-018-0049-z
17.
YehCD, RichardsonCD, CornJE. Advances in genome editing through control of DNA repair pathways. Nat Cell Biol, 2019; 21(12):1468–1478; doi: 10.1038/s41556-019-0425-z
18.
LongC, AmoasiiL, MireaultAA, et al.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 2016; 351(6271):400–403; doi: 10.1126/science.aad5725
19.
NelsonCE, HakimCH, OusteroutDG, et al.In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science, 2016; 351(6271):403–407; doi: 10.1126/science.aad5143
20.
TabebordbarM, ZhuK, ChengJKW, et al.In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science, 2016; 351(6271):407–411; doi: 10.1126/science.aad5177
21.
MaederML, StefanidakisM, WilsonCJ, et al.Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med, 2019; 25(2):229–233; doi: 10.1038/s41591-018-0327-9
22.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385(6):493–502; doi: 10.1056/NEJMoa2107454
23.
WenJ, CaoT, WuJ, et al.Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Mol Ther, 2022; 30(1):164–174; doi: 10.1016/j.ymthe.2021.05.010
24.
WangJY, DoudnaJA. CRISPR technology: A decade of genome editing is only the beginning. Science, 2023; 379(6629):eadd8643; doi: 10.1126/science.add8643
25.
WangD, TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019; 18(5):358–378; doi: 10.1038/s41573-019-0012-9
BlairHA. Valoctocogene roxaparvovec: First approval. Drugs, 2022; 82(14):1505–1510; doi: 10.1007/s40265-022-01788-y
28.
KeelerAM, FlotteTR. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): Where are we, and how did we get here?. Annu Rev Virol, 2019; 6(1):601–621; doi: 10.1146/annurev-virology-092818-015530
29.
KeamSJ. Eladocagene exuparvovec: First approval. Drugs, 2022; 82(13):1427–1432; doi: 10.1007/s40265-022-01775-3
30.
TruongDJ, KuhnerK, KuhnR, et al.Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res, 2015; 43(13):6450–6458; doi: 10.1093/nar/gkv601
31.
WuZ, YangH, ColosiP. Effect of genome size on AAV vector packaging. Mol Ther, 2010; 18(1):80–86; doi: 10.1038/mt.2009.255
32.
van HaasterenJ, LiJ, ScheidelerOJ, et al.The delivery challenge: Fulfilling the promise of therapeutic genome editing. Nat Biotechnol, 2020; 38(7):845–855; doi: 10.1038/s41587-020-0565-5
33.
DavisJR, WangX, WitteIP, et al.Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng, 2022; 6(11):1272–1283; doi: 10.1038/s41551-022-00911-4
34.
ChenS, LiuZ, XieW, et al.Compact Cje3Cas9 for efficient in vivo genome editing and adenine base editing. CRISPR J, 2022; 5(3):472–486; doi: 10.1089/crispr.2021.0143
35.
KimDY, ChungY, LeeY, et al.Hypercompact adenine base editors based on transposase B guided by engineered RNA. Nat Chem Biol, 2022; 18(9):1005–1013; doi: 10.1038/s41589-022-01077-5
36.
WaltonRT, ChristieKA, WhittakerMN, et al.Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science, 2020; 368(6488):290–296; doi: 10.1126/science.aba8853
37.
NishimasuH, ShiX, IshiguroS, et al.Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science, 2018; 361(6408):1259–1262; doi: 10.1126/science.aas9129
38.
HuJH, MillerSM, GeurtsMH, et al.Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature, 2018; 556(7699):57–63; doi: 10.1038/nature26155
39.
SchmelasC, GrimmD. Split Cas9, not hairs—Advancing the Therapeutic Index of CRISPR Technology. Biotechnol J, 2018; 13(9):e1700432; doi: 10.1002/biot.201700432
40.
ZetscheB, VolzSE, ZhangF. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol, 2015; 33(2):139–142; doi: 10.1038/nbt.3149
41.
ChenY, ZhiS, LiuW, et al.Development of highly efficient dual-AAV split adenosine base editor for in vivo gene therapy. Small Methods, 2020; 4(9):2000309; doi: 10.1002/smtd.202000309
42.
ZhiS, ChenY, WuG, et al.Dual-AAV delivering split prime editor system for in vivo genome editing. Mol Ther, 2021; 30(1):283–294; doi: 10.1016/j.ymthe.2021.07.011
43.
LevyJM, YehWH, PendseN, et al.Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng, 2020; 4(1):97–110; doi: 10.1038/s41551-019-0501-5
44.
LiJ, SunW, WangB, et al.Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther, 2008; 19(9):958–964; doi: 10.1089/hum.2008.009
45.
CheriyanM, PedamalluCS, ToriK, et al.Faster protein splicing with the Nostoc punctiforme DnaE intein using non-native extein residues. J Biol Chem, 2013; 288(9):6202–6211; doi: 10.1074/jbc.M112.433094
46.
ChewWL, TabebordbarM, ChengJK, et al.A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods, 2016; 13(10):868–874; doi: 10.1038/nmeth.3993
47.
LimCKW, GapinskeM, BrooksAK, et al.Treatment of a mouse model of ALS by in vivo base editing. Mol Ther, 2020; 28(4):1177–1189; doi: 10.1016/j.ymthe.2020.01.005
48.
WinterJ, LuuA, GapinskeM, et al.Targeted exon skipping with AAV-mediated split adenine base editors. Cell Discov, 2019; 5:41; doi: 10.1038/s41421-019-0109-7
49.
ClementK, ReesH, CanverMC, et al.CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol, 2019; 37(3):224–226; doi: 10.1038/s41587-019-0032-3
50.
FineEJ, AppletonCM, WhiteDE, et al.Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci Rep, 2015; 5:10777; doi: 10.1038/srep10777
51.
ArankoAS, WlodawerA, IwaiH. Nature's recipe for splitting inteins. Protein Eng Des Sel, 2014; 27(8):263–271; doi: 10.1093/protein/gzu028
52.
NishimasuH, RanFA, HsuPD, et al.Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 2014; 156(5):935–949; doi: 10.1016/j.cell.2014.02.001
53.
YuW, WuZ. In vivo applications of CRISPR-based genome editing in the retina. Front Cell Dev Biol, 2018; 6:53; doi: 10.3389/fcell.2018.00053
54.
RasoulinejadSA, MaroufiF. CRISPR-based genome editing as a new therapeutic tool in retinal diseases. Mol Biotechnol, 2021; 63(9):768–779; doi: 10.1007/s12033-021-00345-4
55.
KimK, ParkSW, KimJH, et al.Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res, 2017; 27(3):419–426; doi: 10.1101/gr.219089.116
56.
DolbergTB, MegerAT, BoucherJD, et al.Computation-guided optimization of split protein systems. Nat Chem Biol, 2021; 17(5):531–539; doi: 10.1038/s41589-020-00729-8
57.
KoblanLW, DomanJL, WilsonC, et al.Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol, 2018; 36(9):843–846; doi: 10.1038/nbt.4172
58.
ZafraMP, SchatoffEM, KattiA, et al.Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol, 2018; 36(9):888–893; doi: 10.1038/nbt.4194
59.
KimYB, KomorAC, LevyJM, et al.Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol, 2017; 35(4):371–376; doi: 10.1038/nbt.3803
60.
KomorAC, ZhaoKT, PackerMS, et al.Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv, 2017; 3(8):eaao4774; doi: 10.1126/sciadv.aao4774
61.
WangX, LiJ, WangY, et al.Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion. Nat Biotechnol, 2018; 36(10):946–949; doi: 10.1038/nbt.4198
62.
DomanJL, RaguramA, NewbyGA, et al.Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol, 2020; 38(5):620–628; doi: 10.1038/s41587-020-0414-6
63.
NeugebauerME, HsuA, ArbabM, et al.Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat Biotechnol, 2022; In Press; doi: 10.1038/s41587-022-01533-6
64.
LiangP, DingC, SunH, et al.Correction of beta-thalassemia mutant by base editor in human embryos. Protein Cell, 2017; 8(11):811–822; doi: 10.1007/s13238-017-0475-6
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
